Opus Genetics公司宣布,已与美国食品药品监督管理局就Opgx-lca5针对Lca5相关遗传性视网膜疾病的III期注册试验设计达成共识。这一关键进展标志着该候选疗法的临床开发路径进一步明确,为其后续的注册申请奠定了重要基础。
Opus Genetics公司宣布,已与美国食品药品监督管理局就Opgx-lca5针对Lca5相关遗传性视网膜疾病的III期注册试验设计达成共识。这一关键进展标志着该候选疗法的临床开发路径进一步明确,为其后续的注册申请奠定了重要基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.